Photodiagnosis and photodynamic therapy · 2025
Efficacy of 5-aminolevulinic acid photodynamic therapy for Olsen Grade 3 actinic keratosis: A prospective cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Qinyuan, Luan Jing, Tang Ying, Ma Wenjuan, Wu Wenyu, Chen Shujun
Аннотация
BACKGROUND: Actinic keratosis (AK) is a common cutaneous keratinocyte dysplasia categorized by the Olsen Grade (OG) 1-3. OG 3 AK, which has a higher risk of progressing to cutaneous squamous cell carcinoma (cSCC), presents treatment challenges. While 5-aminolevulinic acid photodynamic therapy (ALA-PDT) is effective for non-hyperkeratotic AK (OG 1-2), its efficacy for OG 3 AK remains debated.
METHODS: To evaluate the efficacy and safety of ALA-PDT for the treatment of OG 3 AK, this single-center prospective cohort study included 127 patients with histopathologically confirmed AK, grouped by the Olsen grading (OG 3, n = 33; OG 1 or 2, n = 94). All patients received four sessions of ALA-PDT and were followed up for 12 months. The primary outcome was initial complete clearance (CC) at 3 months, while sustained CC at 12 months was the secondary outcome. Safety was assessed throughout the study.
RESULTS: The initial CC rates were 87.88 % (29/33) for the OG 3 group and 92.55 % (87/94) for the OG 1/2 group. The sustained CC rates at 12 months were 89.66 % (26/29) and 86.21 % (75/87) for the OG 3 and OG 1/2 groups, respectively. No significant difference was observed between the two groups for either initial CC or sustained CC rates (p > 0.05). Adverse events were mostly mild and transient, though long-lasting erythema at 12 months was more common in the OG 3 group compared with the OG 1/2 group (23.08 % vs. 5.33 %, p = 0.01).
CONCLUSION: ALA-PDT demonstrates favorable efficacy and safety profile for OG 3 AK, supporting ALA-PDT as a valuable non-invasive treatment option for OG 3 AK.
METHODS: To evaluate the efficacy and safety of ALA-PDT for the treatment of OG 3 AK, this single-center prospective cohort study included 127 patients with histopathologically confirmed AK, grouped by the Olsen grading (OG 3, n = 33; OG 1 or 2, n = 94). All patients received four sessions of ALA-PDT and were followed up for 12 months. The primary outcome was initial complete clearance (CC) at 3 months, while sustained CC at 12 months was the secondary outcome. Safety was assessed throughout the study.
RESULTS: The initial CC rates were 87.88 % (29/33) for the OG 3 group and 92.55 % (87/94) for the OG 1/2 group. The sustained CC rates at 12 months were 89.66 % (26/29) and 86.21 % (75/87) for the OG 3 and OG 1/2 groups, respectively. No significant difference was observed between the two groups for either initial CC or sustained CC rates (p > 0.05). Adverse events were mostly mild and transient, though long-lasting erythema at 12 months was more common in the OG 3 group compared with the OG 1/2 group (23.08 % vs. 5.33 %, p = 0.01).
CONCLUSION: ALA-PDT demonstrates favorable efficacy and safety profile for OG 3 AK, supporting ALA-PDT as a valuable non-invasive treatment option for OG 3 AK.